Journal of Medicinal Chemistry
Article
dependent multidrug resistance. Org. Biomol. Chem. 2009, 7, 5166−
MTT, 3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium
bromide
5172.
(19) Perestelo, N. R.; Sanchez-Canete, M. P.; Gamarro, F.; Jimenez,
́
́
̃
I. A.; Castanys, S.; Bazzocchi, I. L. Overcoming human P-glycoprotein-
dependent multidrug resistance with novel dihydro-β-agarofuran
sesquiterpenes. Eur. J. Med. Chem. 2011, 46, 4915−4923.
REFERENCES
■
(1) Cancer: Fact Sheet no. 297; World Health Organization: Geneva,
cessed April 04, 2015).
(2) Wu, Q.; Yang, Z.; Nie, Y.; Shi, Y.; Fan, D. Multi-drug resistance in
cancer chemotherapeutics: Mechanisms and lab approaches. Cancer
Lett. 2014, 347, 159−166.
́ ́
(20) Callies, O.; Sanchez-Canete, M. P.; Gamarro, F.; Jimenez, I. A.;
̃
Castanys, S.; Bazzocchi, I. L. Restoration of chemosensitivity in P-
glycoprotein-dependent multidrug-resistant cells by dihydro-β-agar-
ofuran sesquiterpenes from Celastrus vulcanicola. J. Nat. Prod. 2015, 78,
736−745.
(3) Gottesman, M. M.; Pastan, I.; Ambudkar, S. V. P-glycoprotein
and multidrug resistance. Curr. Opin. Genet. Dev. 1996, 6, 610−617.
(4) Choi, Y. H.; Yu, A. M. ABC transporters in multidrug resistance
and pharmacokinetics, and strategies for drug development. Curr.
Pharm. Des. 2014, 20, 793−807.
́ ́
(21) Cortes-Selva, F.; Jimenez, I. A.; Munoz-Martínez, F.; Campillo,
̃
M.; Bazzocchi, I. L.; Pardo, L.; Ravelo, A. G.; Castanys, S.; Gamarro, F.
Dihydro-β-agarofuran sesquiterpenes: a new class of reversal agents of
the multidrug resistance phenotype mediated by P-glycoprotein in the
protozoan parasite Leishmania. Curr. Pharm. Des. 2005, 11, 3125−
3139.
(5) Sharom, F. J. Complex interplay between the P-glycoprotein
multidrug efflux pump and the membrane: Its role in modulating
protein function. Front. Oncol. 2014, 4, 1−19.
(22) Palmeira, A.; Sousa, E.; Vasconcelos, M. H.; Pinto, M.;
Fernandes, M. X. Structure and ligand-based design of P-glycoprotein
inhibitors: a historical perspective. Curr. Pharm. Des. 2012, 18, 4197−
4214.
(23) Ferreira, R. J.; Ferreira, M.-J. U.; dos Santos, D. J. V. A.
Reversing cancer multidrug resistance: insights into the efflux by ABC
transports from in silico studies. WIREs Comput. Mol. Sci. 2015, 5, 27−
55.
(6) Silva, R.; Vilas-Boas, V.; Carmo, H.; Dinis-Oliveira, R. J.;
Carvalho, F.; Bastos, M. L.; Remiao, F. Modulation of P-glycoprotein
̃
efflux pump: induction and activation as a therapeutic strategy.
Pharmacol. Ther. 2015, 149, 1−123.
(7) Alakhova, D. Y.; Kabanov, A. V. Pluronics and MDR reversal: An
Update. Mol. Pharmaceutics 2014, 11, 2566−2578.
(8) Binkhathlan, Z.; Lavasanifar, A. P-glycoprotein inhibition as a
therapeutic approach for overcoming multidrug resistance in cancer:
current status and future perspectives. Curr. Cancer Drug Targets 2013,
13, 326−246.
(9) Srivalli, K. M. R.; Lakshmi, P. K. Overview of P-glycoprotein
inhibitors: a rational outlook. Braz. J. Pharm. Sci. 2012, 48, 353−367.
(10) Cripe, L. D.; Uno, H.; Paietta, E. M.; Litzow, M. R.; Ketterling,
R. P.; Bennett, J. M.; Rowe, J. M.; Lazarus, H. M.; Luger, S.; Tallman,
M. S. Zosuquidar, a novel modulator of P-glycoprotein, does not
improve the outcome of older patients with newly diagnosed acute
myeloid leukemia: a randomized, placebo-controlled trial of the
Eastern Cooperative Oncology Group 3999. Blood 2010, 116, 4077−
4085.
(11) Callaghan, R.; Luk, F.; Bebawy, M. Inhibition of the multidrug
resistance P-glycoprotein: time for a change of strategy? Drug Metab.
Dispos. 2014, 42, 623−631.
(12) Wu, C. P.; Ohnuma, S.; Ambudkar, S. V. Discovering natural
product modulators to overcome multidrug resistance in cancer
chemotherapy. Curr. Pharm. Biotechnol. 2011, 12, 609−620.
(13) Subburayan, K.; Sugeerappa, L. H. Development of fourth
generation ABC inhibitors from natural products: A novel approach to
overcome cancer multidrug resistance. Anti-Cancer Agents Med. Chem.
2015, 15, 605−615.
(14) Jiao, W.; Wan, Z.; Chen, S.; Lu, R.; Chen, X.; Fang, D.; Wang, J.;
Pu, S.; Huang, X.; Gao, H.; Shao, H. Lathyrol diterpenes as modulators
of P-glycoprotein dependent multidrug resistance: Structure−activity
relationship studies on Euphorbia factor L3 derivatives. J. Med. Chem.
2015, 58, 3720−3738.
(15) Revalde, J. L.; Li, Y.; Hawkins, B. C.; Rosengren, R. J.; Paxton, J.
W. Heterocyclic cyclohexanone monocarbonyl analogs of curcumin
can inhibit the activity of ATP-binding cassette transporters in cancer
multidrug resistance. Biochem. Pharmacol. 2015, 93, 305−317.
(16) Kim, M. K.; Choo, H.; Chong, Y. Water-soluble and cleavable
quercetin-amino acid conjugates as safe modulators for P-glycoprotein-
based multidrug resistance. J. Med. Chem. 2014, 57, 7216−7233.
(17) Reyes, C. P.; Munoz-Martínez, F.; Torrecillas, I. R.; Mendoza,
C. R.; Gamarro, F.; Bazzocchi, I. L.; Nunez, M. J.; Pardo, L.; Castanys,
́
S.; Campillo, M.; Jimenez, I. A. Biological evaluation, structure-activity
́
(24) Torres-Romero, D.; King-Díaz, B.; Jimenez, I. A.; Lotina-
Hennsen, B.; Bazzocchi, I. L. Sesquiterpenes from Celastrus vulcanicola
as photosynthetic inhibitors. J. Nat. Prod. 2008, 71, 1331−1335.
(25) Dugave, Ch.; Demange, L. Cis-trans isomerization of organic
molecules and biomolecules: implications and application. Chem. Rev.
2003, 103, 2475−2532.
(26) Ecker, G.; Huber, M.; Schmid, D.; Chiba, P. The importance of
a nitrogen atom in modulators of multidrug resistance. Mol. Pharmacol.
1999, 56, 791−796.
(27) Li, D.; Chen, L.; Li, Y.; Tian, S.; Sun, H.; Hou, T. ADMET
evaluation in drug discovery. 13. Development of in silico prediction
models for P-glycoprotein substrates. Mol. Pharmaceutics 2014, 11,
716−726.
(28) Dei, S.; Coronnello, M.; Floriddia, E.; Bartolucci, G.; Bellucci,
C.; Guandalini, L.; Manetti, D.; Romanelli, M. N.; Salerno, M.; Bello,
I.; Mini, E.; Teodori, E. Multidrug resistance (MDR) reversers: High
activity and efficacy in a series of asymmetrical N,N-bis(alkanol)amine
aryl esters. Eur. J. Med. Chem. 2014, 87, 398−412.
(29) Ekins, E.; Kim, R. B.; Leake, B. F.; Dantzig, A. H.; Schuetz, E.
G.; Lan, L.-B.; Yasuda, K.; Shepard, R. L.; Winter, M. A.; Schuetz, J.
D.; Wikel, J. H.; Wrighton, S. A. Three-dimensional quantitative
structure-activity relationships of inhibitors of P-glycoprotein. Mol.
Pharmacol. 2002, 61, 964−973.
(30) Chen, L.; Li, Y.; Zhao, Q.; Peng, H.; Hou, T. ADME evaluation
in drug discovery. 10. Predictions of P-glycoprotein inhibitors using
recursive partitioning and naive Bayesian classification techniques. Mol.
Pharmaceutics 2011, 8, 889−900.
(31) Chan, K.-F.; Wong, I. L. K.; Kan, J. W. Y.; Yan, C. S. W.; Chow,
L. M. C.; Chan, T. H. Amine linked flavonoid dimers as modulators
for P-glycoprotein-based multidrug resistance: Structure-activity
relationship and mechanism of modulation. J. Med. Chem. 2012, 55,
1999−2014.
(32) Ferreira, A.; Pousinho, S.; Fortuna, A.; Falcao, A.; Alves, G.
Flavonoid compounds as reversal agents of the P-glycoprotein-
mediated multidrug resistance: biology, chemistry and pharmacology.
Phytochem. Rev. 2015, 14, 233−272.
(33) Maier, M. E. Design and synthesis of analogues of natural
products. Org. Biomol. Chem. 2015, 13, 5302−5343.
̃
́
̃
relationships, and three-dimensional quantitative structure-activity
relationship studies of dihydro-β-agarofuran sesquiterpenes as
modulators of P-glycoprotein-dependent multidrug resistance. J.
Med. Chem. 2007, 50, 4808−4817.
(18) Torres-Romero, D.; Munoz-Martínez, F.; Jimenez, I. A.;
́
Castanys, S.; Gamarro, F.; Bazzocchi, I. L. Novel dihydro-β-agarofuran
sesquiterpenes as potent modulators of human P-glycoprotein
(34) Salavati-Niasari, M.; Khosousi, T.; Hydarzadeh, S. Highly
selective esterification of tert-butanol by acetic acid anhydride over
alumina-supported InCl3, GaCl3, FeCl3, ZnCl2, CuCl2, NiCl2, CoCl2
and MnCl2 catalysts. J. Mol. Catal. A: Chem. 2005, 235, 150−153.
̃
J
J. Med. Chem. XXXX, XXX, XXX−XXX